Patients with hepatitis C virus (HCV) infections that were treated with the novel protease inhibitor, boceprevir, had better virologic responses than patients treated with peginterferon and ribavirin ...

Small Molecule Combination Therapies Are Being Investigated to Increase Response Rates Researchers agree that now is a crucial time to be involved in hepatitis C virus (HCV) research. “Current ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...

The FDA is notifying health-care professionals about potential dangerous drug interactions between the hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis, Merck) and certain anti-HIV ...

"In patients with chronic infection with [HCV] genotype 1 who do not have a sustained response to therapy with peginterferon–ribavirin, outcomes after retreatment are suboptimal," write Bruce R. Bacon ...

AbbVie may have an edge over Gilead in the race to bring a faster-acting, all-oral hepatitis C cure to market, but it’s a slight one. Yesterday the drugmaker presented detailed Phase-III data for its ...

Hepatitis C was discovered in 1989. It took 22 years for these two – the first antiviral drugs to cure the infection – to be discovered and developed. (4) Invirase (1995) was the first HIV protease ...

HANGZHOU, China & RESEARCH TRIANGLE PARK, NC & SAN FRANCISCO--(BUSINESS WIRE)--Ascletis and Presidio announced today that they have entered into an exclusive licensing agreement for Presidio’s ...

Patients treated with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) and antiretrovirals (ARVs) for HIV rarely receive drug combinations that are contraindicated, according to real-world ...